Home

Chen Schor

CIK 1340875 · President & CEO · last filed 2026-06-23

Chen Schor is a President & CEO who has filed 66 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ACET, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$5.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $115.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$115.8K

Companies

6

Total Filings

66

Lifetime Open-Market Net

-$5.08M

Filer Profile

Reported Address
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, 2ND FLOOR
NEWTON, MA 02459
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACET President & CEO 9,536 $9.52 $90.8K -$5.13M 35 2026-06-23
KPTI Director 15,508 $1.61 $25.0K $0 7 2026-05-26
Adicet Bio, Inc. (TORC) Delisted President and CEO 319,480 — — $53.5K 6 2019-12-06
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Director 8,371 $0.75 $6.3K $0 4 2018-12-21
MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted Former President and CEO 37,178 — — $0 5 2016-07-22
EPIX Pharmaceuticals, Inc. (EPIX) Delisted Chief Business Officer 7,312 $0.20 $1.5K $0 6 2009-03-03

Recent Filings

66 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 ACET Grant (A) — $0 EDGAR
2026-05-26 KPTI Grant (A) +15,508 $0 EDGAR
2026-03-27 ACET Grant (A) — $0 EDGAR
2026-01-27 ACET Tax (F) −1,755 -$14.8K EDGAR
2025-05-29 KPTI Grant (A) — $0 EDGAR
2025-02-04 ACET Grant (A) — $0 EDGAR
2025-01-28 ACET Tax (F) −28,101 -$25.9K EDGAR
2024-06-07 ACET Grant (A) — $0 EDGAR
2024-05-30 KPTI Grant (A) — $0 EDGAR
2024-01-26 ACET Mixed +55,010 -$36.7K EDGAR
Showing 1–10 of 66
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.